Kenya bans HIV drug

Kenya bans HIV drug


James Macharia
Kenya’s Health Minister

The Kenyan Health ministry has directed officials across the country to stop prescribing a HIV drug linked to birth defects in HIV-positive women.

The directive signed by the Director of Medical Services Jackson Kioko, urged county health directors to ensure that pregnant and breastfeeding mothers to whom a front-line drug, dolutegravir (DTG), has been prescribed, continue their current prescription until they stop breastfeeding.

But those of child bearing age between 15 and 49 years, who are on the drug, should be given the first-line treatment Efavirenz.

In a memo to county directors of health, Dr Kioko said the drug, which was launched in the Kenyan market last year, was not recommended for pregnant and breastfeeding women “due to limited safety data”.

He, however, added that through a circular in June 2017, the ministry had recommended the use of DTG in alternative regimen for people with HIV and have intolerance to Efavirenz, people who inject drugs and are on anti-retroviral therapy or new patients in the same category.

– Daily Nation

About author

You might also like

Zambia dismisses reports of Ebola outbreak in capital

Health authorities in Zambia on Tuesday September 4, dismissed reports that the country has recorded its first Ebola case. Reports in some local media reported that the country recorded its

Why President Buhari must invest in Maternal and Child Health

Feature By DevComs Maternal death is one of the daunting consequences of inadequate health care during pregnancies and within 42 days after termination of pregnancy. The mere fact that it

Orelope-Adefulire applauds CSOs in fight against HIV/ AIDs, others 

By Adeola Tukuru,  Abuja Senior Special Assistant to the President on Sustainable Development Goals, SSAP-SDGs, Princess Adejoke Orelope-Adefulire, has applauded the multiple functions of the ‎Civil Society Organisation (CSOs) in

0 Comments

No Comments Yet!

You can be first to comment this post!

Leave a Reply